Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.73 USD | -1.55% |
|
-1.39% | -7.15% |
Feb. 05 | Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay | MT |
Feb. 05 | Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration